The DOI matches its Crossref record, with a small difference in title or year; 37 of the 37 references it cites were found in a registry or an index.
Glucose-Dependent Insulinotropic Polypeptide
Open accessAbstract
OBJECTIVE: To evaluate the glucose dependency of glucose-dependent insulinotropic polypeptide (GIP) effects on insulin and glucagon release in 10 healthy male subjects ([means ± SEM] aged 23 ± 1 years, BMI 23 ± 1 kg/m2, and HbA1c 5.5 ± 0.1%). RESEARCH DESIGN AND METHODS: Saline or physiological doses of GIP were administered intravenously (randomized and double blinded) during 90 min of insulin-induced hypoglycemia, euglycemia, or hyperglycemia. RESULTS: During hypoglycemia, GIP infusion caused greater glucagon responses during the first 30 min compared with saline (76 ± 17 vs. 28 ± 16 pmol/L per 30 min, P < 0.008), with similar peak levels of glucagon reached after 60 min. During euglycemia, GIP infusion elicited larger glucagon responses (62 ± 18 vs. −11 ± 8 pmol/L per 90 min, P < 0.005). During hyperglycemia, comparable suppression of plasma glucagon (−461 ± 81 vs. −371 ± 50 pmol/L per 90 min, P = 0.26) was observed with GIP and saline infusions. In addition, during hyperglycemia, GIP more than doubled the insulin secretion rate (P < 0.0001). CONCLUSIONS: In healthy subjects, GIP has no effect on glucagon responses during hyperglycemia while strongly potentiating insulin secretion. In contrast, GIP increases glucagon levels during fasting and hypoglycemic conditions, where it has little or no effect on insulin secretion. Thus, GIP seems to be a physiological bifunctional blood glucose stabilizer with diverging glucose-dependent effects on the two main pancreatic glucoregulatory hormones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with these clinical observations, recent studies indicate that agonism of the GIP receptor is important for maximal stimulation of insulin secretion from human pancreatic β cells (20, 21).”
From Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2) (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Self-citationCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 887
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 596
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Self-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Self-citationVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationDunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–351 of 351
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.01.001 · Cited by 1
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F. M., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 1
SØRUM, N. E., Warnøe, J., Holst, J. J., Hartmann, B., Gasbjerg, L. S., Størling, J., Bergmann, M. L., Dejgaard, T. F., Christensen, M. B., Campbell, J. E., et al. (2026) · Diabetes · doi:10.2337/db25-1128 · Cited by 1
Self-citationWallentowitz, L., García, M. G., Atorrasagasti, C., Harms, C., Huhn, E. A., Roser, P., Verlohren, S., Giesen, E. M., & Blois, S. M. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10053-6 · Cited by 3
Yie, J., Mou, Z., & Liu, X. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag029 · Cited by 1
Shestakova, E. A., Ilyin, А. V., Деев, А. Д., Shestakova, M. V., & Dedov, I. I. (2014) · Problems of Endocrinology · doi:10.14341/probl201460132-35 · Cited by 1
Effects of glucose-dependent insulinotropic polypeptide on glucagon
Christensen, M., & Knop, F. K. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000093 · Cited by 1
Self-citationAdiponectin, Diabetes, and the Cardiovascular System
Gasbarrino, K., Boutari, C., Filippaios, A., Gianopoulos, I., Daskalopoulou, S. S., & Mantzoros, C. S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_8 · Cited by 1
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Nomoto, H., & Miyoshi, H. (2017) · British Journal of Research · doi:10.21767/2394-3718.100021 · Cited by 1
Metabolic Outcomes of Surgery for Non-Obese Type 2 Diabetes
Hur, K. Y. (2020) · Daehan nae'si'gyeong bog'gang'gyeong oe'gwa haghoeji/Journal of minimally invasive surgery · doi:10.7602/jmis.2020.23.2.57 · Cited by 1
Double et triple agonistes : rôle du glucagon
Scheen, A. J. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.006 · Cited by 1
Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?
Halimi, S., Charbonnel, B. H., Monguillon, P., & Dejager, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30011-0
Genetic Pleiotropies of Obesity
Kahali, B., & Speliotes, E. K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8642-8_6
On the Impact of Bariatric Surgery on Glucose Homeostasis
Abrahamsson, N. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Glucometabolic gut hormones: beyond the incretin effect
Sonne, D. P. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000092
Paracrine regulation of glucagon secretion from pancreatic islets
Elliott, A. D. (2014)
Ileal Fatty Acid Sensing Mechanisms Regulate Glucose Homeostasis In Vivo
Zadeh‐Tahmasebi, M. (2015) · TSpace (University of Toronto)
Tv, S., Мусина, Н. Н., Ts, P., Budeeva, S. V., Гончаревич, О. К., Сергеевна, Т. Е., Dronova, I. V., & Tashireva, L. A. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00210
Effects of Exercise on Incretin Hormones
Toghi-Eshghi, S. R. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r30g3hd88
Utilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Glucagon in treatment of hypoglycemia - novelties
Brož, J., Malinovská, J., Brunerová, L., & Urbanová, J. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.022
Biosynthesis, secretion, and action of glucagon
Lefèbvre, P. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch10
In Vivo Imaging of the Pancreas and Gut Hormone Receptors
Eriksson, O., Hulsart‐Billström, G., Mitran, B., Puuvuori, E., & Velikyan, I. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165498-00262
Efficience et précision du contrôle glycémique dans le diabète : symphonie inachevée ?
Monnier, L., Halimi, S., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.11.005
Tirzepatide: Revolutionary Drug in Management of “Diabesity”
Chouhan, V., Spal, S., & Kumar, R. (2022) · International Journal of Medical and Dental Sciences · doi:10.18311/ijmds/2022/636
Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care
Gnanathayalan, S., & Sumanatilleke, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_110_23
Zhu, J., Huang, Y., Luo, Y., Wen, Y., Li, H., Li, W., Deng, Y., Shao, J., Huang, H., & Zhu, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3894429/v1
Considerations Pertaining to Implant Sites for Cell-Based Insulin Replacement Therapies
Marfil‐Garza, B. A., Cuesta‐Gomez, N., & Shapiro, A. M. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_16 · Cited by 1
Babayeva, A., Coşkun, M., Yalçın, M. M., Aktürk, M., Törüner, F. B., Karakoç, M. A., & Altınova, A. E. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01367-9
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004
Hellström, P. M., Javidi, D. J., Webb, D., Tartera, H. O. D., Ud‐din, M., Elias, K., & Sundbom, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5313085/v1
A Neural Network Method for Assessing the Nutritional Requirements of a Patient With Type 2 Diabetes
Mwakalu, S. M., Omwenga, V. O., & Ogao, P. J. (2025) · Applied Computational Intelligence and Soft Computing · doi:10.1155/acis/9955073
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26633796
SØRUM, N. E., Magnussen, T., Hansen, N. L., Nielsen, C. K., Holst, J. J., Hartmann, B., Henriksen, K., Størling, J., Faber, J., Christensen, M. B., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf215 · Cited by 1
Self-citationCheng, D., Sun, M., Huang, J., Luo, S., Chen, H., Jin, S., Zhang, Y., & Yuan, X. (2025) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2025.111192
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.12.005 · Cited by 1
Chasseloup, F. (2022) · theses.fr (ABES) · doi:10.70675/ddec5b6dzf376z4aadz9970zf0bf052c6f02
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Depression Associated with Other Medical Conditions
Sunzeri, F., & Sunzeri, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_12
Virgilio, N., Schön, C., Steiner, N., Schlageter, V., Wilhelm, M., Silva, C. I. F., Gevaert, E., & Prawitt, J. (2026) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2026.109512
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Ajjan, R., Battelino, T., Cos, X., Prato, S. D., Mathieu, C., Almehthel, M. S., Seufert, J., Guerci, B., & Seidu, S. (2026) · The Lancet Primary Care · doi:10.1016/j.lanprc.2026.100193
Milosavljevic, J., Meyer, C., Levine, J. A., & Sachdev, S. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag216
Structure–activity relationship (SAR) of polyphenols on molecular targets in diabetes
Miragliotta, A. M. G., Angelina, E., Gonzalez, R. B., Peruchena, N. M., Torres, A. M., & Ojeda, G. A. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-51074-8.00011-5
Duale und triagonistische Inkretine
Kirchhoff, M., & Schattenberg, J. M. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01015-0
G-protein-coupled receptors (GPCRs) in the treatment of diabetes
Abirami, P. M., & Ramkumar, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33887-8.00018-0
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Kierzkowski, F., Skrzypek, W., Bryl, W., Paczkowska, A., & Hoffmann, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1977433
Metadata
- Authors
- Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- Gentofte Hospital (DK)
- Corresponding author
- Christensen, Mikkel
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-11-13
- Volume
- 60
- Issue
- 12
- Pages
- 3103-3109
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3219957
- OpenAlex
- W2414002317
- Cited by
- 353
- References
- 37
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 31 · 2023: 22 · 2022: 36 · 2021: 31 · 2020: 21 · 2019: 32 · 2018: 29 · 2017: 15 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 17 · 2012: 8
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Fonden
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucose-dependent insulinotropic polypeptide, glucagon secretion, insulin secretion, glucose dependence, hypoglycemia, hyperglycemia, normoglycemia, pancreatic hormone regulation, glucose homeostasis
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Gastric Inhibitory Polypeptide, Glucagon, Humans, Hyperglycemia, Hypoglycemia, Injections, Intraventricular, Insulin, Male, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
